142results about How to "Shorten clotting time" patented technology

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; enhancement of hemostasis; increase in clot lysis time; increase in clot strength; and / or increase in overall clot quality (OCQ) in said patient.

A device, system and method for photometric detection of coagulation in whole blood. The present invention is easy to implement and operate. Furthermore, the present invention has the advantage of being considered to fulfill the desired standard of using photometry for measuring blood coagulation. Also, a photometric coagulation test device for whole blood specimens according to the present invention provides medical accuracy to the home user and, at the same time, is simple to construct. The present invention is also useful for detecting and determining blood agglutination, for example as the results of a serological reaction with an antibody.

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.

The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

A device for coagulating body tissue contains an electrode arrangement comprising a first electrode group and a second electrode group, both of which have strip-shaped electrodes.

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

The invention discloses a traditional Chinese medicine combination for the treatment of gynecological hyperlipemia and a preparation method thereof. 60 portions to 120 portions of glossy privet fruit and 25 portions to 75 portions of charred pollen typhae are comminuted into fine powder of 50 meshes to 120 meshes, and set aside; 100 portions to 180 portions of angelica, 60 portions to 120 potions of motherwort herb, 80 portions to 120 portions of Yerbadetajo Herb, 80 portions to 150 portions of radix pseudoginseng, 25 portions to 75 portions of radices salviae miltiorrhizae, 80 portions to 120 portions of hairy vein agrimony, 25 portions to 75 portions of rhizoma cyperi charcoal, 25 portions to 75 portions of carbonized biota tops, 25 portions to 75 portions of radix codonopsis pilosulae, 25 portions to 75 portions of atractylodes macrocephala are added with 6 times to 20 times of water and then decocted for three times, namely 2 hours, 1.5 hours and 1 hour in sequence. Decoction solution is integrated and filtered; the filtrate is reserved; the filtrate is concentrated; fine powder of glossy privet fruit and charred pollen typhae are added into the concentrated filtrate, mixed evenly, dried and comminuted to fine powder of 60 meshes to 100 meshes, and sieving is carried out to obtain the combination. The drug has obvious treatment effects on symptoms of hypermenorrhea, large menstrual volume presented due to bradymenorrhea, prolonged menstruation, abnormal color quality in menstrual period, pain in the lower abdomen, lumbosacral aching, listlessness and the like, and is characterized by faster onset, high efficacy, few side effects and the like, being a comparatively ideal drug for the treatment of gynecological hyperlipemia.

The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.

A wound dressing is which has haemostatic, coagulation-promoting and biocidal properties and can therefore be utilized particularly for acute wound care. Typical areas of application for acute wound care are, for example, the treatment of gunshot wounds. The wound dressing features selected halloysites which, for example, are applied to textile fibers or non-woven materials.

The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita), the leaves of dioecious nettle (Urtica dioica), kaolin, chitosan, fibrinogen and thrombin. Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with superior and broad spectrum hemostatic capabilities, including the ability to arrest arterial hemorrhage. The invention further provides methods of using the inventive compositions in to reduce or stop bleeding, as well as a variety of apparatuses useful in hemostatic contexts that incorporate the inventive compositions. In one particular embodiment, the invention provides hemostatic dressings in which a polymeric layer incorporating chamomile, nettle, kaolin, chitosan, fibrinogen and thrombin components is applied to a textile or fabric material, for example a non-woven viscose.

The invention relates to a method for applying bletilla striata polysaccharide to a hemostatic material. In the prior art, the hemostatic material is used by directly grinding bletilla tuber into powder, so that the method has the disadvantages of much impurity, incapability of controlling the effective content and inconvenience for use. According to the method disclosed by the invention, orchid, namely a dry bletilla tuber product, is dissolved and extracted by adding water and precipitated and dried by using ethanol to form coarse powder; the method has the advantages of non-complex extraction method, low cost, high effective content, less impurity and good hemostatic effect; after being processed, the coarse powder can be made into products, such as a sponge type material, a hemostatic tooth plug and the like; and the method is widely applied to medicine and biomedical engineering.

The invention discloses a Chinese medicine combination for treating cardio-cerebral vascular diseases, which is composed of raw materials with the following parts by weight: 30-50 parts of radix astragali, 20-25 parts of angelica, 15-20 parts of hemlock parsley, 30-50 parts of salvia miltiorrhiza, 15-20 parts of pseudo-ginseng, 15-20 parts of hawkthorn and 20-30 parts of radix puerariae; the Chinese medicine combination of the invention has ingenious compatibility, simple prescription, broad source of raw materials, low price as well as the efficacies of tonifying both qi and blood, balancing yin and yang, activating blood circulation and dissolving stasis; the Chinese medicine combination can soften blood vessels through reducing blood fat and blood viscosity and eliminating blood scales and finally achieve the purposes of smoothing blood circulation and activating cardio-cerebral function; furthermore, the Chinese medicine combination has unique efficacy for resisting atherosclerosis as well as significant curative effect on cardio-cerebral vascular diseases like coronary heart disease, cerebral thrombosis, and the like; the total clinical effective rate can reach over 95% and the Chinese medicine combination can achieve good preventive and health care effect through long-term oral administration and has safe oral administration and no toxicity and side effect.

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

The invention relates to a preparation method of a Chinese herbal medicine for treating the adult acute pyelonephritis, belonging to the technical field of the Chinese herbal medicine preparation method. Generally, the antibacterial medicine such as penicillin, kanamycin and gentamicin which sometimes have no obvious drug efficacy are used for treating the adult acute pyelonephritis. The technical proposal is that: first, put talc, tuckahoe, agaric, oriental water plantain rhizome, semen plantaginis, barbated skullcup herb, herba polygoni avicularis, fructus kochiae, dyer woad leaf, dyer woad root, weeping forsythia, corydalis, flos hibisci, dandelion, herba patriniae, herba houttuyniae, herba oldenlandiae, pollen typhae, herba agtimoniae, nodus nelumbinis rhizomatis, crinis carbonisatus, herba cirsii, herba ecliptae, raw pagoda-tree pod, raw Chinese rhubarb and raw liquorice root in 1200ml water to steep for thirty minutes; then, use slow fire to boil to 500ml and use gauge to filter the boiled liquor; finally, make into the Chinese herbal medicine for treating the adult acute pyelonephritis. The Chinese herbal medicine has the advantage of an enduring and stable curative effect after an oral dose, thus healing the adult acute pyelonephritis.

The invention relates to a drug for treating purpura. Raw materials to make effective components of the drug include radix astragali (prepared), sweet potato stem and leaf, ligustrum fruit, eclipta, elaginella (prepared), panax notoginseng, peanut sead-coat and liquorice. The raw materials can be made into various oral and external preparations through properly processing and / or acceptable auxiliary materials in pharmaceutics. With efficacies of Qi invigorating and Yin replenishing, and blood cooling and bleeding stopping, the invention is mainly used to treat purpura diseases caused by blood heat from Yin deficiency and Qi deficiency and blood absorbing failure, particularly mild and moderate thrombocytopenia.

This invention relates to a preparation method for calcium chitin characterizing in mixing the chitin with powder of CaCl2, calcium acetate, calcium gluconate, calcium lactate, calcium maltate or citrate calcium malate to be reacted, filtered, cleaned, dewatered, dried, crushed and virus eliminated to get the calcium chitin, which is a new type of hemostatic by acting on the red blood cells in the blood, suppressing soluble fiber protein and activating thrombin so as to arrest bleeding.

The duplex bacteria-free medicine mixer includes injectors, duplex frame on the injectors, push rods stretching into the duplex frame and injector seat as well as characterized nozzles communicated via locking parts with the injector seat, which has inner cavity separated into two sealed hollow areas. The structure with nozzles makes the fibrinogen and the catalyst from the injectors well mixed to raise the hemorrhage arresting effect of the mixing formed gel matter, short the hemagglutination period and speed wound heal. The improved injector seat eliminates the need of power unit and air filter unit resulting in saving in cost and simple operation. In addition, the humanized design of the locking unit, pull rod and support rod also simplifies the operation of the device.

The invention relates to the field of medical consumables for the otolaryngology department, in particular to a traditional Chinese medicine packer for treating nasal mucosa bleeding. The traditional Chinese medicine packer comprises an inflating catheter, a top packer, an inflating rubber bag, a liquid spray rubber bag, traditional Chinese medicine cotton and a nose wing pressure pad, wherein the top packer is arranged at the front end of the inflating catheter, the inflating rubber bag is arranged on the outer side of the front section of the inflating catheter, the liquid spray rubber bag is arranged on the outer side of the inflating rubber bag, a layer of traditional Chinese medicine cotton is arranged on the outer wall of the liquid spray rubber bag, and the nose wing pressure pad is arranged at the end part of a clamping arm. The traditional Chinese medicine packer is simple and reasonable in structure and easy and convenient to use, a packing and compression combined hemostasis method is adopted, and bleeding is stopped rapidly; besides, nose blood can be prevented from being choked into the trachea or swallowed into the belly, and secondary damage to the nasal mucosa when the packer is taken out can be prevented; with the adoption of the traditional Chinese medicine cotton for assisting in hemostasis, direct percutaneous absorption of a drug can be realized, the resistance of blood capillaries is enhanced, local blood vessel contraction is prompted, and the purpose of rapid hemostasis is achieved, and the packer can promote swelling reduction of the wound surface, wound healing, tissue generation and tissue repair, thereby being good in hemostasis and treatment effect.

In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides' molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.

Disclosed is an external natural montmorillonite emergency life-saving hemostatic agent, which adopts natural montmorillonite as raw material; natural montmorillonite is composed of silica, titanium oxide, alumina, ferric oxide, magnesium oxide, calcium oxide, sodium oxide and potassium oxide; wherein, the total content of silica and alumina is more than 70%; the interlayer spacing of natural montmorillonite is 1.0- 2.0nm; the specific surface area of natural montmorillonite is 30-1000m2 / g; the preparation include the steps: a herbal grinder is adopted to crush the massive natural montmorillonite into particles with different sizes; the particle sizes of the particles are 1micron-1mm; the crushed natural montmorillonite or calcium montmorillonite processed with ion-exchange is processed for 1-24 hours under the temperature of 60- 900 DEG C to obtain external natural montmorillonite emergency life-saving hemostatic agent which has the advantages of simple preparation operation, rich raw materials, cheap price, easy obtaining, convenient application and good hemostatic effect.

The invention relates to a preparation method for a glucomannan acid hydrolyzed product. The method is characterized by: adopting a material of uniform glucomannan having a weight average molecular weight less than 100 kDa; carrying out hydrolyzing for 0.5-10 hours in an acidity range of pH 1.0-pH 3.0 and in a temperature range of 45-100 DEG C to obtain the glucomannan acid hydrolyzed product having special weight average molecular weight. The invention further discloses a method for monitoring a reaction process by adopting pre-detected relative viscosity of the hydrolyzed product, and medical applications of the glucomannan acid hydrolyzed product in digestive tract ulcer and digestive tract bleeding. According to the present invention, the glucomannan acid hydrolyzed product with controllable weight average molecular weight and good uniformity can be obtained through the preparation method provided by the present invention; the preparation method has advantages of simple operation,easy control, suitability of industrial production and the like, and is applicable for preparing the natural-source glucomannan (such as bletilla striata, konjac gel and the like) hydrolyzed products.

The Chinese medicine preparation for treating nephritis and nephrosis syndrome includes the following four kinds of active Chinese medicine components: the component for invigorating spleen and benefiting Qi, the component for promoting blood circulation to disperse blood clots, the component for clearing away heat and promoting urination, and the component for dispelling wetness and benefiting kidney. It has the functions of the components, and is used in treating chronic nephritis, pyelonephritis and nephrosis syndrome. Clinical application shows the Chinese medicine preparation is safe and has total effective rate up to 88.6 % and no toxic side effect.

The present invention relates to tomato extracts or an active fraction thereof for use in preventing or inhibiting the initiation of venous thrombosis and fibrin clot formation in a vein.